Analysed TIZIANA LIFE SCIENCES LTD (TLSA:NASDAQ) News Sources
Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration
03-09-2026
proactiveinvestors.com
Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial
17-09-2026
proactiveinvestors.com
Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab
21-09-2026
yahoo.com
Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial
21-09-2026
proactiveinvestors.com
Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab
28-09-2026
yahoo.com
Tiziana doses first three patients in ALS trial of nasal antibody foralumab
28-09-2026
proactiveinvestors.com
Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)
30-09-2026
yahoo.com
MARKETS LIVE: Wall Street closes mixed as cooling inflation lifts Nasdaq
30-09-2026
proactiveinvestors.com
What is the current price of TIZIANA LIFE SCIENCES LTD (TLSA:NASDAQ)?
The current price of TIZIANA LIFE SCIENCES LTD (TLSA:NASDAQ) is $1.19.
TIZIANA LIFE SCIENCES LTD (TLSA:NASDAQ) absolute price change since previous trading day?
The absolute price change of TIZIANA LIFE SCIENCES LTD (TLSA:NASDAQ) since the previous trading day is $0.06.
TIZIANA LIFE SCIENCES LTD (TLSA:NASDAQ) percentage price change since previous trading day?
The percentage price change of TIZIANA LIFE SCIENCES LTD (TLSA:NASDAQ) since the previous trading day is 5.3097%.
What is the most recent average sentiment score for TIZIANA LIFE SCIENCES LTD (TLSA:NASDAQ)?
The most recent average sentiment score for TIZIANA LIFE SCIENCES LTD (TLSA:NASDAQ) is 72 out of 100.
What is the most recent average sentiment for TIZIANA LIFE SCIENCES LTD (TLSA:NASDAQ)?
The most recent sentiment for TIZIANA LIFE SCIENCES LTD (TLSA:NASDAQ) is .
SEC-8K** Filing Available For TIZIANA LIFE SCIENCES LTD (TLSA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.